Arbutus discontinues AB-161 and coronavirus programs, focuses on HBV; cash runway extended to Q3 2025

Arbutus Biopharma Corp

Discontinuing AB-161 (oral RNA destabilizer) due to pre-clinical toxicology finding; no safety issues in Phase 1 single doses.
Discontinuing coronavirus combination therapy (AB-343) due to unfavorable PK profile in IND-enabling studies.
Dosed first subject in Phase 1a/1b for oral PD-L1 inhibitor AB-101; preliminary data expected H1 2024.
Pipeline changes expected to extend cash runway through Q3 2025.
Ongoing LNP patent litigations against Moderna (claim construction hearing Feb 2024) and Pfizer/BioNTech.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.